All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Ribociclib/Endocrine Therapy Yields Similar pCRs Compared With Chemotherapy in HR+ Early Breast Cancer

May 15th 2025

Neoadjuvant data from the ADAPTcycle trial confirmed the limited benefit of chemotherapy over endocrine therapy in high-risk HR-positive breast cancer.

Emiltatug Ledadotin Shows Early Clinical Activity and Safety in Advanced/Metastatic TNBC

May 15th 2025

Emiltatug Ledadotin generated initial responses and was tolerable in heavily pretreated patients with advanced/metastatic TNBC.

Puxitatug Samrotecan Yields Responses With Manageable Safety in Pretreated HR+/HER2– Advanced Breast Cancer

May 15th 2025

Puxitatug samrotecan demonstrated manageable safety and early efficacy in HR-positive/HER2-negative advanced breast cancer.

FDA Approves Retifanlimab for Advanced Anal Cancer

May 15th 2025

The FDA approved frontline retifanlimab/chemotherapy for metastatic SCAC and retifanlimab monotherapy for metastatic SCAC with progression on chemotherapy.

Adjuvant Pertuzumab Plus Trastuzumab and Chemotherapy Leads to OS Benefit in Early-Stage HER2+ Breast Cancer

May 15th 2025

Adjuvant pertuzumab with trastuzumab and chemotherapy extended OS vs placebo with trastuzumab and chemotherapy in HER2-positive early breast cancer.

T-DXd Improves All Outcomes in Post-Hoc Look of DESTINY-Breast06 in HR+, HER2-Low/-Ultralow Metastatic Breast Cancer

May 15th 2025

Treatment with T-DXd improved outcomes vs chemotherapy in pretreated patients with HR-positive, HER2-low/-ultralow metastatic breast cancer.

First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC

May 15th 2025

First-line eftilagimod alpha plus pembrolizumab and chemotherapy produced responses in advanced nonsquamous non–small cell lung cancer.

First Successful Allogeneic Stem Cell Transplant Using Deceased Donor in Blood Cancer Clinical Trial

May 15th 2025

Huntsman Cancer Institute pioneers a clinical trial using deceased donor stem cells, expanding transplant options for patients with aggressive blood cancers.

FDA Green Lights Companion Diagnostic for Telisotuzumab Vedotin in NSCLC

May 15th 2025

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic for telisotuzumab vedotin in non–small cell lung cancer.

Pembrolizumab-Based Regimen Yields PFS Benefit in Platinum-Resistant Ovarian Cancer

May 15th 2025

Pembrolizumab/paclitaxel with or without bevacizumab improved PFS vs placebo/chemotherapy with or without bevacizumab in platinum-resistant ovarian cancer.

FDA Approval of Penpulimab Expands Treatment Options in Recurrent/Metastatic Non-Keratinizing NPC

May 15th 2025

Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab for recurrent/metastatic non-keratinizing NPC.

Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting

May 15th 2025

Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.

Imlunestrant Plus Abemaciclib Provides Consistent Benefit Across Key Subgroups of ER+ Advanced Breast Cancer

May 14th 2025

Subgroup analyses from EMBER-3 continued to demonstrated benefits with imlunestrant plus abemaciclib in ER-positive advanced breast cancer.

Sitravatinib/Nivolumab Shows Modest Activity in Progressive Metastatic Clear Cell RCC Before Trial Termination

May 14th 2025

Sitravatinib plus nivolumab did not produce significant antitumor activity or survival outcomes in patients with progressive metastatic clear cell RCC.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression

May 14th 2025

The FDA approved telisotuzumab vedotin for pretreated advanced NSCLC harboring high c-MET protein overexpression.

Molecular Profiling Yields Insights into Glioblastoma

May 14th 2025

Two new tumor profiling studies offer insights into how to classify such brain tumors and how they evolve after treatment.

FDA Approves Belzutifan for Advanced Pheochromocytoma and Paraganglioma

May 14th 2025

The FDA has approved belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Rhenium (Re186) Obisbemeda Shows Initial Safety, Clinical Benefit in Leptomeningeal Metastases

May 14th 2025

The novel injectable radiotherapy 186RNL showed safety and clinical activity as treatment for patients with leptomeningeal metastases.

AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL

May 14th 2025

Longer-term phase 1/2 data with AB-101 plus rituximab showed high, durable responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Generic Eltrombopag Is Now Available for Severe Aplastic Anemia and Immune Thrombocytopenia

May 14th 2025

Generic formulations of eltrombopag are now available for severe aplastic anemia and immune thrombocytopenia.